The estimated Net Worth of V Sebastian Pastore is at least $551 Mille dollars as of 11 December 2013. V Pastore owns over 27,006 units of Hookipa Pharma Inc stock worth over $67,230 and over the last 16 years V sold HOOK stock worth over $483,869.
V has made over 7 trades of the Hookipa Pharma Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently V exercised 27,006 units of HOOK stock worth $107,484 on 11 December 2013.
The largest trade V's ever made was selling 30,054 units of Hookipa Pharma Inc stock on 6 December 2013 worth over $483,869. On average, V trades about 7,439 units every 123 days since 2009. As of 11 December 2013 V still owns at least 12,733 units of Hookipa Pharma Inc stock.
You can see the complete history of V Pastore stock trades at the bottom of the page.
V's mailing address filed with the SEC is 929 NORTH RUSSELL STREET, , PORTLAND, OR, 97227.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... e Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: